Pasithea Therapeutics Corp. (KTTAW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Jul 15Jul 21Jul 27Aug 4Aug 10Aug 13Aug 24Sep 2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1959.7x

Market Cap

$55085.60

MomentumView details →

1D Return

+174.07%

YTD Return

−47.52%

RSI (14)

50.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1959.7x

Market Cap

$55085.60

RSI (14)

50.6

MomentumView details →

1D Return

+174.07%

YTD Return

−47.52%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−42.72%

ROA (TTM)

−41.18%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+74.59%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+77.07%

EBITDA YoY

−78.91%

EarningsView details →

EPS (Actual)

−$0.16

EPS Surprise

0.00%

Beats (12Q)

0/12

Next Q EPS Est

−$0.21

Avg Surprise (4Q)

−9.26%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

26.25x

Quick Ratio

26.25x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−21.29M

Op. CF (TTM)

−17.78M

Next earningsDec 2, 2026 →

Latest newsMore news →

The FDA granted Orphan Drug Designation to Pasithea Therapeutics' PAS-004 for the treatment of ALS.95d ago

Similar companies

Celularity Inc.CELUW Cingulate Inc.CINGW Coeptis Therapeutics Holdings, Inc.COEPW Vincerx Pharma, Inc.VINC SeaStar Medical Holding CorporationICUCW Revelation Biosciences, Inc.REVBW Find similar companies →

Latest newsMore news →

The FDA granted Orphan Drug Designation to Pasithea Therapeutics' PAS-004 for the treatment of ALS.95d ago